Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin With Antidepressant Therapy in Depression-obesity Comorbidity
NCT07654179Recruiting
- Sponsor
- Riphah International University
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised trial of liquid metformin (Aspargo Labs) in major depressive disorder (MDD) and obesity (2 arms), sponsored by Riphah International University. Primary endpoints: Change in Severity of the depression at 1 month and Change in BMI at 3 months. Started Jun 2026; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
major depressive disorder (MDD)obesity
Beyond the preview
Go deeper on NCT07654179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654179.